Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study of its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens, specifically the Der p 1 allergen from house dust mites [1][2][5] Company Overview - Polyrizon is a biotechnology company focused on developing intranasal products using its proprietary Capture & Contain (C&C) platform, which creates a hydrogel barrier to protect against allergens and viruses [6] Study Results - The pre-clinical study showed that PL-14 significantly limited allergen diffusion, with only 1.07% of the allergen penetrating after one hour, 1.14% after two hours, and 13.6% after four hours [8] - The allergen load used in the study was significantly higher than typical exposure levels, suggesting that PL-14 may provide strong protection even in extreme conditions [3] Market Potential - The Allergy Immunotherapy market is projected to grow from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, with a CAGR of 7.9%, driven by the rising prevalence of allergies and advancements in treatment methodologies [4] Future Plans - Polyrizon plans to advance its preclinical development program and initiate clinical studies to support regulatory pathways for PL-14 and other candidates within the C&C platform [5][9]
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy